Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04685876
Other study ID # 20-790
Secondary ID
Status Recruiting
Phase Phase 3
First received
Last updated
Start date June 4, 2021
Est. completion date December 2024

Study information

Verified date January 2024
Source The Cleveland Clinic
Contact Fabio Rodriguez, MD
Phone 216-444-9950
Email rodrigf3@ccf.org
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The study will prospectively compare the analgesic efficacy of TAP blocks with liposomal bupivacaine, plain bupivacaine, and placebo in patients who are scheduled for major abdominal surgery. The primary aim is to assess the duration of the local analgesia (determined by pinprick and cold) in all four quadrants. Comparing opioid consumption and pain scores is a secondary aim. All aims will be assessed over 72 hours or the duration of hospitalization if shorter.


Description:

The investigators propose a randomized double-blind trial comparing TAP blocks with liposomal bupivacaine, plain bupivacaine, and placebo in patients having elective abdominal surgery. After eligibility is confirmed, patients will receive complete information about the study both verbally and in writing. Informed consent will be obtained from the patients prior to randomization and study-specific procedures. Randomization will be based on computer-generated codes and use random-sized blocks. Allocations will be concealed until the morning of surgery where they will be provided by a web-based system. Randomization will be stratified by study site and chronic opioid use, defined by opioid use for more than 30 consecutive days within three preoperative months, at a daily dose of 15 mg or more of morphine or equivalent. Randomization will also be stratified according to anticipated type of surgery (open vs. laparoscopic-assisted). Clinicians doing the blocks will not be involved in data collection and all the evaluators will be blinded to group allocations. All blocks will be performed preoperatively or after induction of anesthesia by attending anesthesiologists or regional anesthesia fellows who are experienced in TAP blocks. Premedication will be administered at the discretion of the attending anesthesiologist and standard monitors will be used. Patients will be given 1 g oral acetaminophen an hour before surgery, and an additional 500 mg every 6 hours for 72 hours after surgery starting with oral intake. Patients will be randomly assigned to: 1) 4-quadrant TAP block with liposomal bupivacaine; 2) 4-quadrant TAP block with plain bupivacaine; or, 3) placebo (normal saline). An in-plane ultrasound will be guide TAP blocks. Two subcostal injections will be applied by placing the probe midline and then moving lateral along the subcostal margin identifying area between the rectus abdominis sheath and the transversus abdominis muscle. The lateral two TAP block injections will be applied in the midaxillary line between the thoracic cage and iliac crest between external oblique and transversus abdominis muscles. Once the target area is positioned, the following injections will be given, based on randomization: Liposomal bupivacaine. 40 ml of plain bupivacaine 0.25% will be mixed with 20 ml liposomal bupivacaine and 20 ml of saline. 20 ml of the mix will be injected at each location of the 4-quadrant TAP block. Plain bupivacaine group. 50 ml of plain bupivacaine 0.5% will be combined with 30 ml of normal saline making a total of 80 ml. 20 ml will be injected at each location of the 4-quadrant TAP block. Placebo group; patients will receive total of 80 ml of normal saline, injected 20 ml in each of the four-quadrant sites. General anesthesia will be induced using propofol or etomidate, fentanyl, and rocuronium to facilitate intubation. Anesthesia will be maintained with sevoflurane or isoflurane, along with opioids and muscle relaxants as clinically indicated. However, intraoperative analgesic use will be limited to fentanyl, a short-acting opioid. Postoperatively, patients will be given intravenous patient-controlled analgesia and nurses will be free to give additional opioid as clinically indicated. Hydromorphone will be the default drug, but fentanyl will be substituted if necessary. Clinicians blinded to trial drug will adjust analgesic management as necessary in an effort to keep verbal response pain scores (details below) <4 points on a 0-10 scale, with 10 being worst pain. When patients no longer need PCA, they will be switched to as-needed hydromorphone or fentanyl. A single dose of dexamethasone (4-8 mg) will be permitted for PONV prophylaxis, and inhaled steroids will be permitted as necessary to treat reactive airway disease. The use of non-steroidal anti-inflammatory drugs and gabapentinoids will be allowed as part of the ERAS approach (enhanced recovery after surgery) according to hospital's clinical practice. Other opioid-sparing medications such as ketamine and lidocaine patches will not be permitted through the initial 72 postoperative hours. Patients will be allowed to receive prophylactic anti-emetic (first choice ondansetron) intraoperatively based on the risk assessment for nausea and vomiting. Postoperative anti-emetics for symptomatic treatment will also be allowed; again ondansetron will be the first choice.


Recruitment information / eligibility

Status Recruiting
Enrollment 237
Est. completion date December 2024
Est. primary completion date December 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years to 85 Years
Eligibility Inclusion Criteria: - Written informed consent; - 18-85 years old; - ASA Physical Status 1-3; - Scheduled for elective open or laparoscopic-assisted abdominal surgery; - Anticipated hospitalization of at least three nights; - Expected requirement for parenteral opioids for at least 72 hours for postoperative pain; - Able to use IV PCA systems. Exclusion Criteria: - Hepatic disease, e.g. twice the normal levels of liver enzymes; - Kidney disease, e.g. twice the normal level of serum creatinine; - Bupivacaine sensitivity or known allergy; - Women who are pregnant or breastfeeding; - Anticoagulants considered to be a contraindication for TAP blocks; - Surgeries with high port sites; - Weight <50 kg.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Liposomal bupivacaine
4-quadrant TAP block with liposomal bupivacaine
Plain bupivacaine
4-quadrant TAP block with plain bupivacaine
Normal saline
placebo (normal saline).

Locations

Country Name City State
United States Cleveland Clinic Cleveland Ohio

Sponsors (1)

Lead Sponsor Collaborator
The Cleveland Clinic

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Time to return of sensation The investigator evaluate when patients feels both ice and pinprick in at least 6 of the 8 designated test locations, or 75% of the covered points if the TAP block did not initially cover all eight locations. 72 hours
Secondary Opioid Consumption The investigators will compare the 3 randomized groups on opioid consumption over the first 72 hours 72 hours
See also
  Status Clinical Trial Phase
Completed NCT01611376 - Impedance Cardiography During Major Abdominal Surgery Phase 4
Recruiting NCT05556174 - Intraoperative Lung Protective Ventilation Needs Periodic Lung Recruitment Maneuvers N/A
Completed NCT03633123 - D-PLEX 310: Safety and Efficacy of D-PLEX in the Prevention of Post Abdominal Surgery Incisional Infection Phase 2
Terminated NCT03684304 - The Effect of Abdominal Binder Use on Postoperative Pain and Mobility in Patients Undergoing Pelvic Surgery N/A
Active, not recruiting NCT02817893 - Comparison of Respiratory Variations of the Pulse Oximetry Plethysmographic Raw Signal and Pulse Pressure During Abdominal Surgery (PLETHYSMO) N/A
Completed NCT04120740 - Validation of Two Acitivity Monitors in Three Inpatient Populations.
Recruiting NCT03700749 - FALCON Trial Testing Measures to Reduce Surgical Site Infection Phase 3
Completed NCT01389648 - Pre-operative Physiotherapy to Prevent Post-operative Complications N/A
Withdrawn NCT00557843 - Continuous Bupivacaine Infusion Following Colonic Surgery N/A
Active, not recruiting NCT01839617 - Study Comparing Early and Late Nutrition in Cancer Patients Undergoing Abdominal Surgery N/A
Terminated NCT04887922 - Preoperative and Postoperative Incentive Spirometry in Patients Undergoing Major Abdominal Surgery N/A
Completed NCT04730141 - Effect of Mobilization Protocol on Mobilization N/A
Completed NCT00683150 - Perioperative Kinetics of Reactive Hyperemia Using Noninvasive Digital Thermal Monitoring N/A
Active, not recruiting NCT03933306 - Intraoperative Goal-directed Blood Pressure and Dexmedetomidine on Outcomes Phase 4
Recruiting NCT05268432 - Development, Intraoperative Demonstration and Visualization of Surgical Assistance Functions
Not yet recruiting NCT04747535 - Continuous Positive Airway Pressure After Abdominal Surgery N/A
Not yet recruiting NCT05253586 - Versius Or Laparoscopic Abdominal Hernia REpair
Recruiting NCT06374849 - Intraoperative Sufentanil and Chronic Postsurgical Pain in Non-major Scheduled Abdominal Surgery Phase 4
Recruiting NCT05246605 - Postoperative Hypoxia and Body Position N/A
Completed NCT04233424 - D-PLEX 311: Safety and Efficacy of D-PLEX in the Prevention of Post Abdominal Surgery Incisional Infection Phase 3